Subunit Vaccine Market 2022-2028

Description

List of Tables

Title:Global Subunit Vaccine Market Size, Share & Trends Analysis Report, by Product Type (Protein Antigen, and Polysaccharide Antigen), by Production Type (Denaturing of Proteins, and Genetic Engineering), by Immune Responses Type (Antigen-Presenting Cells (APCs), Cell-Mediated Immunity, Cytokines, Mucosal, and Others), and by Disease (Infectious Disease, Diphtheria, Tetanus and Pertussis (DTP), HPV, Measles, Mumps and Rubella (MMR), and Others) Forecast Period (2022-2028).

The global subunit vaccine market is anticipated to grow at a significant CAGR of 10.9% during the forecast period. The factors fueling the growth of the subunit vaccine market include increasing demand for immunization and better safety as compared to traditional vaccines. The benefits offered by subunit vaccines such as long immunity offered and the low-risk rate associated with the subunit vaccines are propelling the market growth. The challenges associated with the production process of subunit vaccines are hindering the growth of the market.

The global subunit vaccine market is segmented based on the product type, production type, immune response type, and disease. Based on the product type, the market is segmented into protein antigen and polysaccharide antigen. Based on the production type, the market is segmented into denaturing of proteins, and genetic engineering. Based on the type of the immune response, the market is segmented into antigen-presenting cells (APCs), cell-mediated immunity, cytokines, mucosal, and others. Based on the disease, the market is sub-segmented into infectious disease, diphtheria, tetanus and pertussis (DTP), HPV, measles, mumps, and rubella (MMR), and others. The above-mentioned segments can be customized as per the requirements. Based on the production type, the global subunit vaccines market is classified into denaturing of proteins and genetic engineering. The denaturing of proteins segment held a considerable market share owing to the easy production process.

Geographically market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is the leading market for subunit vaccines owing to increased technological advancements and R&D.

The major companies serving the global subunit vaccine market include GE Healthcare Life Sciences, GlaxoSmithKline PLC, Merck & Co. Inc., Reber Genetics, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2019, a private biotechnology company, Algenex SL, delivered disruptive technology for recombinant biologics manufacturing and announced that one of its industrial partners has submitted a dossier to the European Medicines Agency (EMA) for a recombinant subunit vaccine manufacturing by using Algenex' proprietary CrisBio® technology. The submission targeted European marketing authorization through the centralized approval system. This was the first vaccine manufactured using Algenex' CrisBio® technology to be submitted for regulatory approval.

Research Methodology

The market study of the global subunit vaccine market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.
Whitepapers, research papers, and news blogs.
Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Subunit Vaccine Market Research and Analysis by Product Type

2. Global Subunit Vaccine Market Research and Analysis by Production Type

3. Global Subunit Vaccine Market Research and Analysis by Immune Responses Type

4. Global Subunit Vaccine Market Research and Analysis by Disease

The Report Covers:

Comprehensive Research Methodology of the global subunit vaccine market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global subunit vaccine market.
Insights about market determinants that are stimulating the global subunit vaccine market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026551

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Impact of COVID-19 on the Global Subunit Vaccine Market
Recovery Scenario of Global Subunit Vaccine Market
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. GE Healthcare Life Sciences
  - 3.1.1.1. Overview
  - 3.1.1.2. Financial Analysis
  - 3.1.1.3. SWOT Analysis
  - 3.1.1.4. Recent Developments
- 3.1.2. GlaxoSmithKline PLC
  - 3.1.2.1. Overview
  - 3.1.2.2. Financial Analysis
  - 3.1.2.3. SWOT Analysis
  - 3.1.2.4. Recent Developments
- 3.1.3. Merck & Co. Inc.
  - 3.1.3.1. Overview
  - 3.1.3.2. Financial Analysis
  - 3.1.3.3. SWOT Analysis
  - 3.1.3.4. Recent Developments
- 3.1.4. Reber Genetics
  - 3.1.4.1. Overview
  - 3.1.4.2. Financial Analysis
  - 3.1.4.3. SWOT Analysis
  - 3.1.4.4. Recent Developments
- 3.1.5. Sanofi S.A.
  - 3.1.5.1. Overview
  - 3.1.5.2. Financial Analysis
  - 3.1.5.3. SWOT Analysis
  - 3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

4.1. Global Subunit Vaccine Market by Product Type
- 4.1.1. Protein Antigen
- 4.1.2. Polysaccharide Antigen
4.2. Global Subunit Vaccine Market by Production Type
- 4.2.1. Denaturing of Proteins
- 4.2.2. Genetic Engineering
4.3. Global Subunit Vaccine Market by Immune Responses Type
- 4.3.1. Antigen-Presenting Cells (APCS)
- 4.3.2. Cell-Mediated Immunity
- 4.3.3. Cytokines (Direct Th1 Or Th2 Immune Responses)
- 4.3.4. Mucosal
- 4.3.5. Others
4.4. Global Subunit Vaccine Market by Disease
- 4.4.1. Infectious Disease
- 4.4.2. Diphtheria, Tetanus and Pertussis (DTP)
- 4.4.3. HPV
- 4.4.4. Measles, Mumps and Rubella (MMR)
- 4.4.5. Others

5. Regional Analysis

5.1. North America
- 5.1.1. US
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. Algenex S.L.
6.2. Arbutus Biopharma Corp.
6.3. Astellas Pharma Inc,
6.4. Astrazeneca PLC
6.5. Emergent Biosolutions
6.6. Indian Immunologicals Ltd.
6.7. QED Biosciences Inc.
6.8. Mitsubishi Tanabe
6.9. Novartis International AG
6.10. Pfizer, Inc.
6.11. Roche Holding AG
6.12. Shenzhen Kangtai Biological Products
6.13. Takeda Pharmaceuticals Company Ltd.
6.14. Vical Inc.
6.15. Virbac